Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 13/20 | 0.52 |
| ▸ | CNR1 | P21554 | 12/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006991 | 1.00 | THRB (0.54) | THRBTHRACNR2CNR1NPC1 | |
| SCHEMBL31007007 | 1.00 | THRB (0.54) | THRBTHRACNR2CNR1NPC1 | |
| SCHEMBL31006960 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL31006980 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL31006982 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL31006973 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL31006967 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL7336231 | 0.81 | THRA (0.57) | THRBTHRACNR1NPC1TP53 | |
| SCHEMBL31006976 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 | |
| SCHEMBL31007018 | 0.81 | THRB (0.55) | THRBTHRACNR2NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233964-A | Single component delivery system for nucleic acids | 宾夕法尼亚大学理事会 | 2024-12-31 | — | — | CN | disclosed |
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252677-A1 | ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS | TLR3, TLR9, ADAR | THRB 4164/4885THRA 2158/4885CNR2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.